University of Cambridge completes first human trial of an AI-designed vaccine targeting all coronaviruses, showing safety and ...

Jefferies Global Healthcare Conference 2026 June 4, 2026 3:10 PM EDTCompany ParticipantsAlexandria Forbes - CEO, ...

So AbCellera is a company based in Vancouver, Canada, also with offices in Montreal, Canada and in Sydney, Australia. Founded in 2012 out of our Founder and CEO, Carl Hansen's lab from the University ...

These results support darovasertib plus Xalkori as a potential new standard of care if approved for HLA A*02:01-negative ...

RBI Grade B Admit Card 2026 has been released. The direct link to download the hall tickets is given here.  | Competitive Exams ...

New vaccine technology created with the help of artificial intelligence could provide immunity against whole families of ...

Researchers are refining autologous tumor-infiltrating lymphocyte treatment while testing CAR T-cell therapies in new tumor ...

At ASCO 2026, companies debuted data that could hold the potential to disrupt the frontline treatment paradigm for various subtypes of NSCLC.

MAIA’s novel telomere-targeting therapy being evaluated as a third-line treatment for advanced non-small cell lung cancer ...

Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare ...

Lupeng Pharmaceutical today announced that the National Medical Products Administration (NMPA) has granted accelerated ...

Shares of ADC Therapeutics SA (NYSE:ADCT) were trading at $1.54, down 49%, or $1.54, after the firm disclosed top-line data from the phase III Lotis-5 confirmatory trial testing Zynlonta ...